Shares of Enochian Biosciences Inc (OTCMKTS:ENOB) rose 10.9% on Wednesday . The stock traded as high as $6.20 and last traded at $5.28, approximately 117,524 shares were traded during mid-day trading. An increase of 138% from the average daily volume of 49,381 shares. The stock had previously closed at $4.76.
The firm has a 50-day simple moving average of $4.65 and a 200-day simple moving average of $5.73.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new stake in shares of Enochian Biosciences in the 1st quarter worth $60,000. Northern Trust Corp purchased a new stake in shares of Enochian Biosciences in the second quarter worth about $49,000. Charles Schwab Investment Management Inc. purchased a new stake in Enochian Biosciences in the 2nd quarter worth approximately $69,000. Wells Fargo & Company MN acquired a new stake in Enochian Biosciences during the second quarter valued at $72,000. Finally, United Capital Financial Advisers LLC acquired a new stake in shares of Enochian Biosciences during the 2nd quarter valued at about $105,000.
Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.
Read More: What is meant by holder of record?
Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.